VT
RPRX icon

Vise Technologies’s Royalty Pharma RPRX Stock Holding History

Vise Technologies’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Buy
23,958
+13,307
+125% +$693K 0.02% 669
2026
Q1 		$412K Hold
10,651
– – 0.01% 983
2025
Q4 		$412K Buy
10,651
+1,822
+21% +$69.5K 0.01% 989
2025
Q3 		$312K Sell
8,829
-612
-6% -$22.2K 0.01% 869
2025
Q2 		$340K Buy
+9,441
New +$313K 0.01% 795

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vise Technologies's RPRX Position: Q2 2026 in Review

Vise Technologies increased its Royalty Pharma (RPRX) stake by 125% in Q2 2026, buying an estimated $693K and bringing the position to 23,958 shares worth $1.34M. The position accounts for 0.02% of the portfolio, ranked #669.

Vise Technologies first reported a position in RPRX in Q2 2025 and has held it in 5 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Vise Technologies held 23,958 shares of Royalty Pharma worth $1.34M as of Q2 2026.
  • Vise Technologies bought 13,307 Royalty Pharma shares in Q2 2026, an estimated $693K.
  • Royalty Pharma made up 0.02% of Vise Technologies's portfolio in Q2 2026, its #669 holding.
  • Vise Technologies first reported a position in Royalty Pharma in Q2 2025 and has held it in 5 quarters since.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Vise Technologies's 13F filing for Q2 2026, filed 11 Aug 2026.